When it comes to anti-diabetic medications, our study showed that SGLT-2 inhibitors were associated with decreased risk of SARS-CoV-2 infections and COVID-19 hospitalizations, that insulin and sulphonylurea were associated with increased risk of COVID-19 hospitalizations and that insulin was associated with increased risk of COVID-19 death. This evidence concerns the gene SLC5A2 and COVID-19.